LUTETIUM (177LU) OXODOTREOTIDE

DRUG2 trials

Sponsors

Antwerp University Hospital, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Conditions

The study population includes all patients aged over 18 with a neuroendocrine tumor grade I and II and a clinical indication for PRRT.neuroendocrine tumours

Phase 4

Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial)

RecruitingCTIS2022-502703-30-00

Antwerp University Hospitalneuroendocrine tumours

Start: 2023-06-28Target: 270Updated: 2025-09-24

Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with long-acting Somatostatin Analogues – ATSA trial

RecruitingCTIS2023-505884-35-00

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingThe study population includes all patients aged over 18 with a neuroendocrine tumor grade I and II and a clinical indication for PRRT.

Start: 2024-06-17Target: 34Updated: 2024-10-03

Related Papers

Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocol

BMJ Open2025-07-01